Publikationen

Dam, S., Tscherne, A., Engels, L., Sutter, G., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2025). Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses. Scientific Reports, 15, Article 10586. https://doi.org/10.1038/s41598-025-95479-9
Details anzeigen

Guilfoyle, K., Mirolo, M., van, van der, Lombardo, M. S., Störk, T., Rimmelzwaan, G., Ludlow, M., & Osterhaus, A. (2025). Susceptibility of calf lung slice cultures to H5N1 influenza virus. Emerging Microbes & Infections, 14(1), Article 2432368. https://doi.org/10.1080/22221751.2024.2432368
Details anzeigen

Quiñones-Parra, S. M., Gras, S., Nguyen, T. H. O., Farenc, C., Szeto, C., Rowntree, L. C., Chaurasia, P., Sant, S., Boon, A. C. M., Jayasinghe, D., Rimmelzwaan, G. F., Petersen, J., Doherty, P. C., Uldrich, A. P., Littler, D. R., Rossjohn, J., & Kedzierska, K. (2025). Molecular determinants of cross-strain influenza A virus recognition by αβ T cell receptors. Science Immunology, 10(104), Article eadn3805. https://doi.org/10.1126/sciimmunol.adn3805
Details anzeigen

Aregay, A., Slunečko, J., Korva, M., Bogovic, P., Resman Rus, K., Knap, N., Beicht, J., Kubinski, M., Saletti, G., Avšič-Županc, T., Steffen, I., Strle, F., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins. Npj Vaccines, 9, Article 141. https://doi.org/10.1038/s41541-024-00936-7
Details anzeigen

Kubinski, M., Beicht, J., Gerlach, T., Aregay, A., Osterhaus, A. D. M. E., Tscherne, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2024). Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infection. Vaccines, 12(1), Article 105. https://doi.org/10.3390/vaccines12010105
Details anzeigen

Leroux-Roels, I., Prajeeth, K. C., Aregay, A., Nair, N., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., Kardinahl, S., Pelz, S., Bauer, S., D’Onofrio, V., Alhatemi, A., Jacobs, B., De Boever, F., Porrez, S., Waerlop, G., Punt, C., Hendriks, B., von, van de, et al. (2024). Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against rift valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial. The Lancet: Infectious Diseases, 24(11), 1245–1253. https://doi.org/10.1016/S1473-3099(24)00375-X
Details anzeigen

Meineke, R., Agac, A., Knittler, M.-C., Ludlow, M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Respiratory syncytial virus glycoprotein G impedes CX3CR1-activation by CX3CL1 and monocyte function. Npj Viruses, 2, Article 63. https://doi.org/10.1038/s44298-024-00075-9
Details anzeigen

Prajeeth, C. K., Zdora, I., Saletti, G., Friese, J., Gerlach, T., Wilken, L., Beicht, J., Kubinski, M., Puff, C., Baumgärtner, W., Kortekaas, J., Wichgers Schreur, P. J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice. Emerging Microbes & Infections, 13, Article 2373313. https://doi.org/10.1080/22221751.2024.2373313
Details anzeigen

Waldock, J., Cox, R. J., Engelhardt, O. G., Ascough, S., Osterhaus, A., Rimmelzwaan, G. F., Ludlow, M., Tregoning, J. S., McDonald, J. U., Buchholz, U. J., Jeeninga, R. E., Sande, C., & Chiu, C. (2024). Inno4Vac workshop report part 2: RSV-controlled human infection model (CHIM) strain selection and immune assays for RSV CHIM studies, November 2021, MHRA, UK. Influenza and Other Respiratory Viruses, 18(10), Article e70013. https://doi.org/10.1111/irv.70013
Details anzeigen

Agac, A., Kolbe, S. M., Ludlow, M., Osterhaus, A., Meineke, R., & Rimmelzwaan, G. F. (2023). Host responses to respiratory syncytial virus infection. Viruses, 15(10), Article 1999. https://doi.org/10.3390/v15101999
Details anzeigen

Schweitzer, F., Letoha, T., Osterhaus, A., & Prajeeth, C. K. (2025). Impact of tick-borne Orthoflaviviruses infection on compact human brain endothelial barrier. International Journal of Molecular Sciences, 26(5), Article 2342. https://doi.org/10.3390/ijms26052342
Details anzeigen

Kubinski, M., Beicht, J., Gerlach, T., Aregay, A., Osterhaus, A. D. M. E., Tscherne, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2024). Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infection. Vaccines, 12(1), Article 105. https://doi.org/10.3390/vaccines12010105
Details anzeigen

Leroux-Roels, I., Prajeeth, K. C., Aregay, A., Nair, N., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., Kardinahl, S., Pelz, S., Bauer, S., D’Onofrio, V., Alhatemi, A., Jacobs, B., De Boever, F., Porrez, S., Waerlop, G., Punt, C., Hendriks, B., von, van de, et al. (2024). Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against rift valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial. The Lancet: Infectious Diseases, 24(11), 1245–1253. https://doi.org/10.1016/S1473-3099(24)00375-X
Details anzeigen

Prajeeth, C. K., Zdora, I., Saletti, G., Friese, J., Gerlach, T., Wilken, L., Beicht, J., Kubinski, M., Puff, C., Baumgärtner, W., Kortekaas, J., Wichgers Schreur, P. J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice. Emerging Microbes & Infections, 13, Article 2373313. https://doi.org/10.1080/22221751.2024.2373313
Details anzeigen

Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T., Baumgärtner, W., Sutter, G., Osterhaus, A., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. Frontiers in Immunology, 14, Article 1177324. https://doi.org/10.3389/fimmu.2023.1177324
Details anzeigen

Kubinski, M., Beicht, J., Zdora, I., Biermann, J., Puff, C., Gerlach, T., Tscherne, A., Baumgärtner, W., Osterhaus, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). A recombinant modified vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection. Frontiers in Immunology, 14, Article 1182963. https://doi.org/10.3389/fimmu.2023.1182963
Details anzeigen

Kubinski, M., Beicht, J., Zdora, I., Saletti, G., Kircher, M., Petry-Gusmag, M., Steffen, I., Puff, C., Jung, K., Baumgärtner, W., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Prajeeth, C. K. (2023). Cross-reactive antibodies against Langat virus protect mice from lethal tick-borne encephalitis virus infection. Frontiers in Immunology, 14, Article 1134371. https://doi.org/10.3389/fimmu.2023.1134371
Details anzeigen

Nair, N., Osterhaus, A., Rimmelzwaan, G., & Prajeeth, C. K. (2023). Rift Valley fever virus: infection, pathogenesis and host immune responses. Pathogens, 12(9), Article 1174. https://doi.org/10.3390/pathogens12091174
Details anzeigen

Pilchová, V., Prajeeth, C. K., Jendrny, P., Twele, F., Meller, S., Pink, I., Volk, H. A., Osterhaus, A., von Köckritz-Blickwede, M., & Schulz, C. (2023). β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: in vitro validation with focus on saliva from COVID-19 patients for scent dog training. In 32nd Annual Meeting of the Society of Virology: abstracts (P 267).
Details anzeigen

Pilchová, V., Prajeeth, C. K., Jendrny, P., Twele, F., Meller, S., Pink, I., Fathi, A., Addo, M. M., Volk, H. A., Osterhaus, A., Köckritz-Blickwede, M. v., & Schulz, C. (2023). β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: in vitro validation with focus on saliva from COVID-19 patients for scent dog training. Journal of Virological Methods, 317, 114733. https://doi.org/10.1016/j.jviromet.2023.114733
Details anzeigen

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2023). FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. iScience, 26(4), Article 106309. https://doi.org/10.1016/j.isci.2023.106309
Details anzeigen

Meineke, R. (2022). Inhibition of Host Kinase Activity: Effects on Influenza A Virus Infection and Host Cell Signaling. https://nbn-resolving.org/urn:nbn:de:gbv:95-117384
Details anzeigen

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2022). FDA-approved inhibitors of RTK/Raf signaling potently impair multiple steps of in vitro and ex vivo influenza A virus infections. Viruses, 14(9), Article 2058. https://doi.org/10.3390/v14092058
Details anzeigen

Becker, T., Elbahesh, H., Reperant, L. A., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2021). Influenza vaccines: successes and continuing challenges. The Journal of Infectious Diseases, 224(Supplement 4), 405–S419. https://doi.org/10.1093/infdis/jiab269
Details anzeigen

Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021). Aging and options to halt declining immunity to virus infections. Frontiers in Immunology, 12, Article 681449. https://doi.org/10.3389/fimmu.2021.681449
Details anzeigen

Ricke-Hoch, M., Stelling, E., Lasswitz, L., Gunesch, A. P., Kasten, M., Zapatero-Belinchón, F. J., Brogden, G., Gerold, G., Pietschmann, T., Montiel, V., Balligand, J.-L., Facciotti, F., Hirsch, E., Gausepohl, T., Elbahesh, H., Rimmelzwaan, G. F., Höfer, A., Kühnel, M. P., Jonigk, D., et al. (2021). Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 16(8), Article e0255335. https://doi.org/10.1371/journal.pone.0255335
Details anzeigen

Di, H., Elbahesh, H., & Brinton, M. A. (2020). Characteristics of human OAS1 isoform proteins. Viruses, 12(2: 152). https://doi.org/10.3390/v12020152
Details anzeigen

Meineke, R., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2020). Differential susceptibility of pandemic H1N1 and seasonal H3N2 Influenza A viruses to clinically-approved small molecule kinase inhibitors. In Stiftung Tierärztliche Hochschule Hannover (Ed.), 13th Graduate School Days: 20/21 November 2020 / Stiftung Tierärztliche Hochschule Hannover (Zoo V 05). Stiftung Tierärztliche Hochschule Hannover.
Details anzeigen

Saletti, G., Gerlach, T., Jansen, J. M., Molle, A., Elbahesh, H., Ludlow, M., Li, W., Bosch, B.-J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2020). Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Scientific Reports, 10: 21447. https://doi.org/10.1038/s41598-020-78506-9
Details anzeigen

Bergmann, S., & Elbahesh, H. (2019). Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses. Virology, 534, 54–63. https://doi.org/10.1016/j.virol.2019.05.020
Details anzeigen